[en] Spinal muscular atrophy (SMA) is a rare, progressive neuromuscular disease characterized by loss of motor neurons and muscle atrophy. Untreated infants with type 1 SMA do not achieve major motor milestones, and death from respiratory failure typically occurs before 2 years of age. Individuals with types 2 and 3 SMA exhibit milder phenotypes and have better functional and survival outcomes. Herein, a systematic literature review was conducted to identify factors that influence the prognosis of types 1, 2, and 3 SMA. In untreated infants with type 1 SMA, absence of symptoms at birth, a later symptom onset, and a higher survival of motor neuron 2 (SMN2) copy number are all associated with increased survival. Disease duration, age at treatment initiation, and, to a lesser extent, baseline function were identified as potential treatment-modifying factors for survival, emphasizing that early treatment with disease-modifying therapies (DMT) is essential in type 1 SMA. In patients with types 2 and 3 SMA, factors considered prognostic of changes in motor function were SMN2 copy number, age, and ambulatory status. Individuals aged 6-15 years were particularly vulnerable to developing complications (scoliosis and progressive joint contractures) which negatively influence functional outcomes and may also affect the therapeutic response in patients. Age at the time of treatment initiation emerged as a treatment-effect modifier on the outcome of DMTs. Factors identified in this review should be considered prior to designing or analyzing studies in an SMA population, conducting population matching, or summarizing results from different studies on the treatments for SMA.
Disciplines :
Pediatrics Neurology
Author, co-author :
Baranello, Giovanni
Gorni, Ksenija
Daigl, Monica
Kotzeva, Anna
Evans, Rachel
Hawkins, Neil
Scott, David A.
Mahajan, Anadi
Muntoni, Francesco
Servais, Laurent ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques
Language :
English
Title :
Prognostic Factors and Treatment-Effect Modifiers in Spinal Muscular Atrophy.
Farrar, M.A. & Kiernan, M.C. The genetics of spinal muscular atrophy: progress and challenges. Neurotherapeutics 12, 290–302 (2015).
Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
Brzustowicz, L.M. et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature 344, 540–541 (1990).
Lefebvre, S. et al. Correlation between severity and SMN protein level in spinal muscular atrophy. Nat. Genet. 16, 265–269 (1997).
Lorson, C.L., Hahnen, E., Androphy, E.J. & Wirth, B. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophyc. Proc. Natl. Acad. Sci. U S A 96, 6307–6311 (1999).
Feldkötter, M., Schwarzer, V., Wirth, R., Wienker, T.F. & Wirth, B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am. J. Hum. Genet. 70, 358–368 (2002).
Butchbach, M.E.R. Copy number variations in the survival motor neuron genes: implications for spinal muscular atrophy and other neurodegenerative diseases. Front. Mol. Biosci. 3, 7 (2016).
Chen, T.-H. New and developing therapies in spinal muscular atrophy: from genotype to phenotype to treatment and where do we stand? Int. J. Mol. Sci. 21, 3297 (2020).
Talbot, K. & Tizzano, E.F. The clinical landscape for SMA in a new therapeutic era. Gene. Ther. 24, 529–533 (2017).
Munsat, T.L. & Davies, K.E. International SMA Consortium Meeting (26–28 June 1992, Bonn, Germany). Neuromuscul. Disord. 2, 423–428 (1992).
Zerres, K. & Rudnik-Schöneborn, S. Natural history in proximal spinal muscular atrophy. Clinical analysis of 445 patients and suggestions for a modification of existing classifications. Arch. Neurol. 52, 518–523 (1995).
Al Dakhoul, S. Very severe spinal muscular atrophy (Type 0). Avicenna. J. Med. 7, 32–33 (2017).
Lally, C., Jones, C., Farwell, W., Reyna, S.P., Cook, S.F. & Flanders, W.D. Indirect estimation of the prevalence of spinal muscular atrophy Type I, II, and III in the United States. Orphanet. J. Rare Dis. 12, 175 (2017).
Harada, Y. et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J. Neurol. 249, 1211–1219 (2002).
Munsat, T.L. International SMA Collaboration. Neuromuscul Disord 1, 81 (1991).
Bladen, C.L. et al. Mapping the differences in care for 5,000 spinal muscular atrophy patients, a survey of 24 national registries in North America, Australasia and Europe. J. Neurol. 261, 152–163 (2014).
Finkel, R.S. et al. Observational study of spinal muscular atrophy type I and implications for clinical trials. Neurology 83, 810–817 (2014).
Kolb, S.J. et al. Natural history of infantile-onset spinal muscular atrophy. Ann. Neurol. 82, 883–891 (2017).
Munsat, T. & Davies, K. Spinal muscular atrophy 32nd ENMC international workshop Naarden, The Netherlands, 10–12 March 1995. Neuromuscul. Disord. 6, 125–127 (1996).
Prior, T.W. Perspectives and diagnostic considerations in spinal muscular atrophy. Genet. Med. 12, 145–152 (2010).
Crawford, T.O. et al. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study. PLoS One 7, e33572 (2012).
D'Amico, A., Mercuri, E., Tiziano, F.D. & Bertini, E. Spinal muscular atrophy. Orphanet. J. Rare Dis. 6, 71 (2011).
Kaufmann, P. et al. Observational study of spinal muscular atrophy type 2 and 3: functional outcomes over 1 year. Arch. Neurol. 68, 779–786 (2011).
Wadman, R.I. et al. Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4. J. Neurol. Neurosurg. Psychiatry 88, 365–367 (2017).
Kaneko, K., Arakawa, R., Urano, M., Aoki, R. & Saiito, K. Relationships between long-term observations of motor milestones and genotype analysis results in childhood-onset Japanese spinal muscular atrophy patients. Brain. Dev. 39, 763–773 (2017).
Wijngaarde, C.A. et al. Natural course of scoliosis and lifetime risk of scoliosis surgery in spinal muscular atrophy. Neurology 93, e149–e158 (2019).
Farrar, M.A., Vucic, S., Johnston, H.M., du Sart, D. & Kiernan, M.C. Pathophysiological insights derived by natural history and motor function of spinal muscular atrophy. J. Pediatr. 162, 155–159 (2013).
Markowitz, J.A., Singh, P. & Darras, B.T. Spinal muscular atrophy: a clinical and research update. Pediatr. Neurol. 46, 1–12 (2012).
Chung, B.H.Y., Wong, V.C.N. & Ip, P. Spinal muscular atrophy: survival pattern and functional status. Pediatrics 114, e548–553 (2004).
Wang, C.H. et al. Consensus statement for standard of care in spinal muscular atrophy. J. Child Neurol. 22, 1027–1049 (2007).
Mercuri, E. et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscul. Disord. 28, 103–115 (2018).
Finkel, R.S. et al. Diagnosis and management of spinal muscular atrophy: Part 2: Pulmonary and acute care; medications, supplements and immunizations; other organ systems; and ethics. Neuromuscul. Disord. 28, 197–207 (2018).
Tizzano, E.F. & Finkel, R.S. Spinal muscular atrophy: a changing phenotype beyond the clinical trials. Neuromuscul. Disord. 27, 883–889 (2017).
Spinraza [EMA prescribing information]. (Biogen, Badhoevedorp, The Netherlands, 2017). . Accessed December 2020.
Spinraza [US prescribing information]. (Biogen, Badhoevedorp, The Netherlands, 2020). . Accessed December 2020.
European Medicines Agency. Zolgensma (onasemnogene abeparvovec-xioi). (2020). Accessed December 2020.
Zolgensma [prescribing information]. (AveXis Inc., Bannockburn, IL, 2021). . Accessed December 2020.
Evrysdi [highlights of prescribing information]. (Genentech, South San Francisco, CA, 2020). . Accessed December 2020.
European Medicines Agency [EMA prescribing information]. Evrsydi (risdiplam). https://www.ema.europa.eu/en/medicines/human/EPAR/evrysdi (2021). Accessed May 2021.
National Institute for Health and Care Excellence. Single technology appraisal: user guide for company evidence submission template. (2017). Accessed December 2020.
Hayden, J.A., van der Windt, D.A., Cartwright, J.L., Côté, P. & Bombardier, C. Assessing bias in studies of prognostic factors. Ann. Intern. Med. 158, 280–286 (2013).
Riley, R.D. et al. A guide to systematic review and meta-analysis of prognostic factor studies. BMJ 364, k4597 (2019).
Kent, P., Cancelliere, C., Boyle, E., Cassidy, J.D. & Kongsted, A. A conceptual framework for prognostic research. BMC Med. Res. Methodol. 20, 172 (2020).
Riley, R.D. et al. Prognosis Research Strategy (PROGRESS) 2: prognostic factor research. PLoS Med 10, e1001380 (2013).
Matthews, J.N. & Altman, D.G. Statistics notes. Interaction 2: Compare effect sizes not P values. BMJ 313, 808 (1996).
Matthews, J.N. & Altman, D.G. Interaction 3: How to examine heterogeneity. BMJ 313, 862 (1996).
Bertini, E. et al. Safety and efficacy of olesoxime in patients with type 2 or non-ambulatory type 3 spinal muscular atrophy: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol. 16, 513–522 (2017).
Muntoni, F. et al. Long-term follow-up of patients with type 2 and non-ambulant type 3 spinal muscular atrophy (SMA) treated with olesoxime in the OLEOS trial. Neuromuscul. Disord. 30, 959–969 (2020).
Finkel, R.S., Weiner, D.J., Mayer, O.H., McDonough, J.M. & Panitch, H.B. Respiratory muscle function in infants with spinal muscular atrophy Type I. Pediatr. Pulmonol. 49, 1234–1242 (2014).
Mercuri, E. et al. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy. N. Engl. J. Med. 378, 625–635 (2018).
Finkel, R.S. et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. N. Engl. J. Med. 377, 1723–1732 (2017).
Qu, Y.J. et al. Association of copy numbers of survival motor neuron gene 2 and neuronal apoptosis inhibitory protein gene with the natural history in a Chinese spinal muscular atrophy cohort. J. Child. Neurol. 30, 429–436 (2015).
Petit, F. et al. Insights into genome-phenotype correations in spinal muscular atrophy: a retrospective study of 103 patients. Muscle Nerve 43, 26–30 (2011).
Rudnik-Schöneborn, S. et al. Genotype-phenotype studies in infantile spinal muscular atrophy (SMA) type I in Germany: implications for clinical trials and genetic counselling. Clin. Genet. 76, 168–178 (2009).
Ge, X., Bai, J., Lu, Y., Qu, Y. & Song, F. The natural history of infant spinal muscular atrophy in China: a study of 237 patients. J. Child. Neurol. 27, 471–477 (2012).
Oskoui, M. et al. The changing natural history of spinal muscular atrophy type 1. Neurology 69, 1931–1936 (2007).
Belter, L. et al. An overview of the Cure SMA membership database: Highlights of key demographic and clinical characteristics of SMA members. J. Neuromuscul. Dis. 5, 167–176 (2018).
Madrid Rodríguez, A., Martínez Martínez, P.L., Ramos Fernández, J.M., Urda Cardona, A. & Martínez Antón, J. Infantile spinal atrophy: our experience in the last 25 years [in Spanish]. An. Pediatr. (Barc.) 82, 159–165 (2015).
Mannaa, M.M., Kalra, M., Wong, B., Cohen, A.P. & Amin, R.S. Survival probabilities of patients with childhood spinal muscular atrophy. J. Clin. Neuromuscul. Dis. 10, 85–89 (2009).
D'Amico, A. et al. Clinical factors as predictors of survival in spinal muscular atrophy type I. J. Paediatr. Child Health 18, S43–S47 (2008).
Gregoretti, C. et al. Survival of patients with spinal muscular atrophy type 1. Pediatrics 131, e1509–e1514 (2013).
Dabbous, O. et al. Survival, motor function, and motor milestones: comparison of AVXS-101 relative to nusinersen for the treatment of infants with spinal muscular atrophy type 1. Adv. Ther. 36, 1164–1176 (2019).
Swoboda, K.J. et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann. Neurol 57, 704–712 (2005).
Kaufmann, P. et al. Prospective cohort study of spinal muscular atrophy types 2 and 3. Neurology 79, 1889–1897 (2012).
Aragon-Gawinska, K. et al. Nusinersen in patients older than 7 months with spinal muscular atrophy type 1: A cohort study. Neurology 91, e1312–e1318 (2018).
Pechmann, A. et al. Evaluation of children with SMA Type 1 under treatment with nusinersen within the expanded access program in Germany. J. Neuromuscul. Dis. 5, 135–143 (2018).
De Sanctis, R. et al. Clinical phenotypes and trajectories of disease progression in type 1 spinal muscular atrophy. Neuromuscul. Disord. 28, 24–28 (2018).
Montes, J. et al. Ambulatory function in spinal muscular atrophy: Age-related patterns of progression. PLoS One 13, e0199657 (2018).
Pera, M.C. et al. Revised upper limb module for spinal muscular atrophy: 12 month changes. Muscle Nerve. 59, 426–430 (2019).
Vuillerot, C., Payan, C., Iwaz, J., Ecochard, R. & Bérard, C.; MFM Spinal Muscular Atrophy Study. Responsiveness of the motor function measure in patients with spinal muscular atrophy. Arch. Phys. Med. Rehabil. 94, 1555–1561 (2013).
Mercuri, E. et al. Patterns of disease progression in type 2 and 3 SMA: Implications for clinical trials. Neuromuscul. Disord. 26, 126–131 (2016).
Mazzone, E. et al. Six minute walk test in type III spinal muscular atrophy: a 12month longitudinal study. Neuromuscul. Disord. 23, 624–628 (2013).
Wadman, R.I. et al. Intragenic and structural variation in the SMN locus and clinical variability in spinal muscular atrophy. Brain Commun. 2, fcaa075 (2020).
Calucho, M. et al. Correlation between SMA type and SMN2 copy number revisited: An analysis of 625 unrelated Spanish patients and a compilation of 2834 reported cases. Neuromuscul. Disord. 28, 208–215 (2018).
Wijngaarde, C.A. et al. Population-based analysis of survival in spinal muscular atrophy. Neurology 94, e1634–e1644 (2020).
Mendell, J.R. Single-dose gene-replacement therapy for spinal muscular atrophy. N. Engl. J. Med. 377, 1713–1722 (2017).
Baranello, G et al. Risdiplam in type 1 spinal muscular atrophy. N. Engl. J. Med. 384, 915–923 (2021).
De Vivo, D.C. et al. Nusinersen initiated in infants during the presymptomatic stage of spinal muscular atrophy: Interim efficacy and safety results from the Phase 2 NURTURE study. Neuromuscul. Disord. 29, 842–856 (2019).
Aragon-Gawinska, K. et al. Sitting in patients with spinal muscular atrophy type 1 treated with nusinersen. Dev. Med. Child Neurol. 62, 310–314 (2020).
Maggi, L. et al. Nusinersen safety and effects on motor function in adult spinal muscular atrophy type 2 and 3. J. Neurol. Neurosurg. Psychiatry 91, 1166–1174 (2020).
Kirschner, J. et al. European ad-hoc consensus statement on gene replacement therapy for spinal muscular atrophy. Eur. J. Paediatr. Neurol. 28, 38–43 (2020).
Lowes, L.P. et al. Impact of age and motor function in a phase 1/2A study of infants with SMA type 1 receiving single-dose gene replacement therapy. Pediatr. Neurol. 98, 39–45 (2019).
Al-Zaidy, S.A. et al. AVXS-101 (Onasemnogene Abeparvovec) for SMA1: comparative study with a prospective natural history cohort. J. Neuromuscul. Dis. 6, 307–317 (2019).
Audic, F. et al. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study. Orphanet. J. Rare Dis. 15, 148 (2020).
Annoussamy, M. et al. Natural history of Type 2 and 3 spinal muscular atrophy: 2-year NatHis-SMA study. Ann. Clin. Transl. Neurol. 8, 359–373 (2021).
Coratti, G. et al. Age and baseline values predict 12 and 24-month functional changes in type 2 SMA. Neuromuscul. Disord. 30, 756–764 (2020).
LoMauro, A., Mastella, C., Alberti, K., Masson, R., Aliverti, A. & Baranello, G. Effect of nusinersen on respiratory muscle function in different subtypes of type 1 spinal muscular atrophy. Am. J. Respir. Crit. Care Med. 200, 1547–1550 (2019).
Trucco, F. et al. Respiratory trajectories in type 2 and non-ambulant 3 Spinal muscular atrophy in the iSMAC cohort study. Neurology. 96, e587–e599 (2021).
Wijngaarde, C.A. et al. Natural history of lung function in spinal muscular atrophy. Orphanet. J. Rare Dis. 15, 88 (2020).
Alves, C.R.R. et al. Whole blood survival motor neuron protein levels correlate with severity of denervation in spinal muscular atrophy. Muscle Nerve 62, 351–357 (2020).
Dangouloff, T. & Servais, L. Clinical evidence supporting early treatment of patients with spinal muscular atrophy: current perspectives. Ther. Clin. Risk Manag. 15, 1153–1161 (2019).
Darras, B.T. et al. Neurofilament as a potential biomarker for spinal muscular atrophy. Ann. Clin. Transl. Neurol. 6, 932–944 (2019).
Bonanno, S. et al. Circulating MyomiRs as potential biomarkers to monitor response to nusinersen in pediatric SMA Patients. Biomedicines 8, 21 (2020).
Kessler, T. et al. Cerebrospinal fluid proteomic profiling in nusinersen-treated patients with spinal muscular atrophy. J. Neurochem. 153, 650–661 (2020).
Olsson, B. et al. NFL is a marker of treatment response in children with SMA treated with nusinersen. J. Neurol. 266, 2129–2136 (2019).
Yuan, P. & Jiang, L. Clinical characteristics of three subtypes of spinal muscular atrophy in children. Brain Dev. 37, 537–541 (2015).
